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Abstract
 
Chemokines dictate regional trafficking of functionally distinct T cell subsets. In rodents and
 
humans, a unique subset of CD4
 
 
 
CD25
 
 
 
 cytotoxic T lymphocyte antigen (CTLA)-4
 
 
 
 regula-
tory T cells (Treg) has been proposed to control peripheral tolerance. However, the molecular
basis of immune suppression and the trafficking properties of Treg cells are still unknown. Here,
we determined the chemotactic response profile and chemokine receptor expression of human
blood-borne CD4
 
 
 
CD25
 
 
 
 Treg cells. These Treg cells were found to vigorously respond to
several inflammatory and lymphoid chemokines. Treg cells specifically express the chemokine
receptors CCR4 and CCR8 and represent a major subset of circulating CD4
 
 
 
 T cells respond-
ing to the chemokines macrophage-derived chemokine (MDC)/CCL22, thymus and activa-
tion-regulated chemokine (TARC)/CCL17, I-309/CCL1, and to the virokine vMIP-I (ligands
of CCR4 and CCR8). Blood-borne CD4
 
 
 
 T cells that migrate in response to CCL1 and
CCL22 exhibit a reduced alloproliferative response, dependent on the increased frequency of
Treg cells in the migrated population. Importantly, mature dendritic cells preferentially attract
Treg cells among circulating CD4
 
 
 
 T cells, by secretion of CCR4 ligands CCL17 and CCL22.
Overall, these results suggest that CCR4 and/or CCR8 may guide Treg cells to sites of antigen
presentation in secondary lymphoid tissues and inflamed areas to attenuate T cell activation.
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Introduction
 
The efficient operation of the immune system is critically
dependent on a complex series of cellular interactions and
movements to specific locations. Chemokines are small
chemotactic cytokines characterized by critically positioned
cysteine residues, which recruit distinct leukocyte subsets
to sites of inflammation and specific microenvironments
within secondary lymphoid tissues (1, 2). Chemokine re-
ceptor expression is exquisitely regulated depending on the
stage of activation and differentiation of T cells and coordi-
nates tissue localization and encounters with APCs (3–5).
One of the fundamental features of the immune system is
its ability to preserve a delicate balance between effector re-
sponses and mechanisms of immunoregulation. Given the
central role of chemokines in the regulation of immunity,
we postulated that some of these molecules could partici-
pate in turning off adaptive immune responses by recruiting
cells with immunoregulatory functions. Various subpopula-
tions of CD4
 
 
 
 T cells that can mediate immunosuppression
both in vitro and in vivo have been described (6–8). Recent
 
studies demonstrated that CD4
 
 
 
CD25
 
 
 
CD45RB
 
low
 
 mem-
ory T cells expressing cytotoxic T lymphocyte antigen
(CTLA)-4 are regulatory T cells (Treg) that mediate toler-
ance to organ-specific self-antigens and can prevent au-
toimmunity and intestinal inflammation in mice (9, 10).
Recently, human peripheral blood CD4
 
 
 
CD25
 
 
 
 T cells
have also been characterized as suppressor T cells (11). We
now report the unique chemotactic response profile of hu-
man blood-borne CD4
 
 
 
CD25
 
 
 
 Treg cells. Treg cells spe-
cifically express the chemokine receptors CCR4 and
 
CCR8 and respond to the chemokines macrophage-
derived chemokine (MDC/CCL22), thymus and activa-
tion-regulated chemokine (TARC/CCL17), I-309/CCL1,
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and the virokine vMIP-I, which are agonistic ligands of
these receptors. Mature DCs producing CCL17 and CCL22
were found to preferentially attract Treg cells, suggesting in-
volvement of these chemokines in Treg cell function.
 
Materials and Methods
 
Chemokines and Abs.
 
CCL1, CCL22, CCL17, vMIP-I,
CCL11, CXCL11, and CXCL12 were purchased from
Dictagene, whereas CXCL13, CCL19, CCL2, CCL3, CCL4,
CCL20, and CCL5 were purchased from R&D Systems. Abs for
various surface molecules were from BD PharMingen unless indi-
cated otherwise. Goat anti–human CCR4 Ab was from Research
Diagnostics Inc. Goat anti–human CCR8 Ab was from Alexis
Corporation. Mouse anti–human CD4 Ab was from Novocastra
Laboratories Ltd. All the conjugated and unconjugated secondary
Abs for immunofluorescent stainings were from Jackson Immu-
noResearch Laboratories.
 
Cell Isolation.
 
Human CD4
 
 
 
 T cells were purified from
healthy donor peripheral blood by Ficoll-Paque (Amersham
Pharmacia Biotech) density gradient centrifugation followed by
isolation with immunomagnetic beads (CD4
 
 
 
 T cell isolation kit;
Miltenyi Biotech). CD4
 
 
 
 T cells were stained with PE-labeled
anti-CD4 and FITC-labeled anti-CD25 mAbs and sorted using a
FACStar™ (Becton Dickinson). Purity was routinely 
 
 
 
95%. Hu-
man monocytes were purified from PBMCs by isolation with im-
munomagnetic beads (Monocyte isolation kit; Miltenyi Biotech)
and cultured in RPMI 1640 with 5% FetalClone I (HyClone), 2
mM L-glutamine, 1 mM sodium pyruvate, 100 U/ml penicillin-
streptomycin (Sigma-Aldrich; complete medium). Dendritic cells
(DCs) were derived from human monocytes by culturing them in
complete medium in the presence of 10 ng/ml of IL-4 (BD
PharMingen) and 800 U/ml of GM-CSF (Myelogen; Schering-
Plough) for 6 d. Maturation of DCs was induced by stimulation
with 1 
 
 
 
g/ml of LPS in fresh complete medium. After 16 h of
stimulation, DCs were washed and cultured for an additional 24 h
in complete medium. Finally, the supernatants were harvested
and tested in chemotaxis.
 
Chemotaxis Assays.
 
Chemotaxis assays were performed using
5-
 
 
 
m pore polycarbonate filters in a Transwell chamber
(Corning Costar Corporation) as described (12). After migra-
tion, 1.35 
 
 
 
 10
 
4
 
 polystyrene beads (Polysciences Inc.) were
added in the lower compartment of the Transwell. Migrated
CD4
 
 
 
 T cells were recovered and stained with anti-CD4,
anti-CD25, and anti-CD45RO mAbs. The number of mi-
grated T cells was measured by flow cytometer acquisition of a
fixed number of beads. For the CCL17 and CCL22 preclear-
ing experiment, 2 ml of DC supernatants were incubated 2 h
at 4
 
 
 
C with 4 
 
 
 
g of mAbs, anti-CCL17, and/or anti-CCL22
(R&D Systems) or an isotype-matched control Ab coupled to
25 
 
 
 
l of protein G sepharose beads (Amersham Pharmacia
Biotech), and after filtration to remove beads, the supernatants
were used for chemotaxis. To calculate specific migration, the
number of cells in each subpopulation in the absence of che-
mokine was subtracted from the number of the corresponding
cell subpopulation migrated in the presence of chemokines.
To evaluate the percentage of specific migration, the number
of specifically migrated CD4
 
 
 
CD25
 
 
 
 T cells was divided by
the total number of specifically migrated cells. To calculate the
chemotactic index, the number of cells migrated in response
to chemokines was divided by the number of spontaneously
migrated cells.
 
Proliferation Assay.
 
To assess the proliferative response of hu-
man CD4
 
 
 
 T cells, we purified allogeneic PBMCs and depleted
T cells with anti-CD3 microbeads (Miltenyi Biotech). Then,
2.5 
 
 
 
 10
 
4
 
 PBMCs were irradiated (3,000 rad) and mixed to
2.5 
 
 
 
 10
 
4
 
 of migrated CD4
 
 
 
 T cells that were depleted or not of
CD25
 
 
 
 T cells by FITC-labeled anti-CD25 mAb followed by
anti-FITC microbeads (FITC multisorting kit; Miltenyi Biotech).
[
 
3
 
H]thymidine incorporation was measured by scintillation
counting on day 3 after a 6-h pulse.
 
Confocal Microscopy Analysis.
 
Slides for double immunofluo-
rescent stainings were postfixed with 4% paraformaldehyde,
blocked with 15% FCS/PBS. After washing, the slides were in-
cubated with the primary Ab. The slides were washed again and
incubated with the fluorocrome (Rhodamine Red-X, Cy2)-con-
jugated secondary Abs. After washing, slides were mounted with
90% glycerol/PBS and analyzed with a confocal microscope
(MRC-1024; Bio-Rad Laboratories) equipped with a 15-mW
Kr/Ar laser.
 
Results
 
Cell surface staining of purified human CD4
 
 
 
 peripheral
blood T cells revealed that 
 
 
 
8–10% of these cells expressed
the IL-2R
 
 
 
 chain CD25. Human CD25
 
 
 
CD4
 
 
 
 T cells
were virtually all CD45RO
 
 
 
, lacked expression of CD69,
were mostly CD45RB
 
low
 
 and CD62L
 
 
 
, and showed consti-
tutive intracellular expression of CTLA-4 (data not shown).
As the mechanism of immunosuppression requires con-
tact between target and Treg cells (13), we reasoned that
Treg cells could use specific chemokine receptors to localize
in the vicinity of effector T cells and/or APCs. We initially
analyzed the migration of purified populations of CD4
 
 
 
 T
cells to a large panel of chemokines (Fig. 1). Analysis of the
percentage of specific migration revealed that 
 
 
 
60% of
CD4
 
 
 
 T cells specifically migrating in response to CCL1
expressed CD25. Human herpesvirus 8 (HHV8)-encoded
vMIP-I, CCL22, and CCL17 also showed preferential
chemotactic activity on CD25
 
 
 
 Treg cells (Fig. 1 a). Given
the fact that CD25
 
 
 
 T cells are CD45RO
 
 
 
 and receptors
for inflammatory chemokines are expressed on effector/
memory T cells, we compared the chemotactic responsive-
ness of CD25
 
 
 
 Treg cells with that of bulk CD25
 
 
 
CD4
 
 
 
 T
cells or only with CD45RO
 
 
 
CD25
 
 
 
 CD4
 
 
 
 T cells. This
analysis revealed that CCL17 and CCL22 were more po-
tent and efficacious but less selective than CCL1 for Treg
cells. The chemotactic index in response to CCL17 and
CCL22 was 
 
 
 
15–18 for CD25
 
 
 
 T cells, 
 
 
 
5–8 for
CD45RO
 
 
 
CD25
 
 
 
 T cells (Fig. 1 b), and 
 
 
 
40% of specifi-
cally migrated CD4
 
 
 
 T cells expressed CD25 (Fig. 1 a). By
contrast, the chemotactic index in response to CCL1 was
only 
 
 
 
4 for CD25
 
 
 
 T cells (Fig. 1 b), but 
 
 
 
50% of specifi-
cally migrated CD4
 
 
 
 T cells were CD25
 
 
 
. It should be
noted that Treg cells also responded to several chemokines
including interferon-inducible T cell 
 
 
 
 chemoattractant (I-
TAC/CXCL11) and Epstein-Barr virus–induced molecule
1 ligand chemokine (ELC/CCL19) (Fig. 1 b). CCL19 ex-
hibited powerful chemotactic activity with a chemotactic
index close to 
 
 
 
100 (Fig. 1 b), but CD25
 
 
 
 Treg cells were
not specifically hyperresponsive to CCL19 when compared 
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with CD4
 
 
 
CD45RO
 
 
 
 T cells (Fig. 1 a). By contrast, the
bulk CD25
 
 
 
 T cell population, which included CD45RA
 
 
 
naive T cells, showed a greater response to the CCR7
ligand CCL19 (Fig. 1 b). Next, we investigated the ability
of CD4
 
 
 
 T cells that migrated in response to CCL1 or
CCL22 to proliferate. In preliminary experiments we con-
firmed the anergic and immunosuppressive phenotype of
purified CD4
 
 
 
CD25
 
 
 
 T cells (data not shown). As ex-
pected, the allogeneic proliferative response of CD4
 
 
 
 T
cells that migrated to CCL1 and CCL22 was markedly re-
duced in comparison to the response of nonmigrated cells
or cells that migrated to CCL19 (Fig. 2 a). Depletion of
Figure 1. Chemotactic response profile of human CD4 CD25 
Treg cells. (a) Specific migration of human CD4 CD25  T cells in
response to CCL1, CCL22, CCL17, vMIP-I, CCL2/MCP-1,
CCL3/MIP-1 , CCL4/MIP-1 , CCL5/RANTES, CCL11/
Eotaxin, CCL19/ELC, CCL20/MIP-3 , CXCL11/I-TAC,
CXCL12/stromal cell–derived factor (SDF)-1, and CXCL13/B
lymphocyte chemoattractant (BLC) (1  g/ml). Mean and SD n   5
experiments for CCL1, CCL17, and CCL22, n     3 for other
chemokines,  *P     0.01. (b) Chemotactic responses of CD25 ,
CD25 CD45RO  and CD25 CD45RO CD4  T cells to CCL1,
CCL22, CCL17, CXCL11, CCL19, and CCL20. Filled circles ( )
represent CD4 CD25 CD45RO  T cells, whereas open circles
( ) represent CD4 CD25 CD45RO  T cells and open squares
( ) represent CD4 CD25  T cells. Mean and SD of one represen-
tative experiment of three performed in triplicate.
Figure 2. Immunoregulatory
activity of CD25  T cells
migrated in response to CCL1
or CCL22. (a) Enrichment
of immunosuppressive activity
amongst CD4  T cells mi-
grated in response to CCL1 or
CCL22. Alloantigen specific
proliferative responses of CD4 
T cells that migrated in re-
sponse to CCL1, CCL22, and
CCL19 were analyzed in tripli-
cate as described in Materials
and Methods. *P     0.05. (b)
Reduction of immunosuppres-
sive activity by depletion of
CD25  T cells from CD4  T
cells migrated in response to
CCL1 or CCL22. After migra-
tion of CD4  T cells in re-
sponse to CCL1 or CCL22, the
cells were split and one part was depleted of CD25  T cells by immunomagnetic bead sorting. CD25 -depleted (CD25 depleted) and nondepleted
populations were then analyzed for their alloantigen specific proliferative response.850 Specific Expression of CCR4 and CCR8 on CD4 CD25  Regulatory T Cells
CD25  cells from CD4  T cells that migrated to CCL1 or
CCL22 resulted in enhanced T cell proliferation (Fig. 2 b).
Based on these findings, we analyzed CCR4 and CCR8
expression on purified CD4 CD25  and CD4 CD25  T
cells. Staining with anti-CCR4 and anti-CCR8 Abs and
analysis by confocal microscopy showed that the great ma-
jority of CD4 CD25  T cells expressed chemokine CCR4
and CCR8 (Fig. 3, a and b). Staining of CD4 CD25  T
cells revealed that a relatively large fraction of these cells
stained positive for CCR4 expression, whereas few cells
expressed CCR8 (Fig. 3, a and b). These findings suggested
coexpression of CCR4 and CCR8 on Treg cells and, con-
sistent with the chemotaxis data, indicated that expression
of CCR8 is more restricted to the Treg cell population
than CCR4. In agreement with coexpression of these re-
ceptors on Treg cells, migration in response to a combina-
tion of suboptimal doses of CCL1 and CCL22 resulted in a
synergistic rather than additive chemotactic effect (Fig. 3
c). Finally, to prove that these receptors were indeed re-
sponsible for the observed migration of Treg cells we took
advantage of the recently described selective CCR8 antag-
onist, MC148, encoded by the virus of Molluscum contagio-
sum (14). In the presence of MC148, specific migration of
Treg cells in response to CCL1 but not CCL22 was com-
pletely abolished, confirming the specific involvement of
CCR8 in CCL1-mediated migration of Treg cells (Fig. 3
d). These findings document that blood-borne human
Treg cells possess a unique chemotactic response profile
and preferentially express the chemokine receptors CCR4
and CCR8.
Overall, our results suggest that CCR4 and CCR8
ligand chemokines CCL1, CCL17, and CCL22 might par-
ticipate in downregulating inflammatory T cell–mediated
responses. Previous work identified specific requirements
for production of these chemokines by T cells and APCs
(15, 16). Mature DCs have been reported to produce large
quantities of CCL17 and CCL22 (17). Thus, we tested the
possibility that Treg cells could be attracted by mature
DCs. Maturation of monocyte-derived DCs was induced
by stimulation with LPS and the supernatant from fully
mature DCs was harvested and tested for the ability to at-
tract Treg cells. In a first series of experiments, we found
that the supernatants obtained from mature DCs, contain-
ing high levels of CCL17 and CCL22 and small amounts of
CCL1, attracted very efficiently CCR4-expressing, but not
CCR8-expressing L1.2 cells (data not shown). We then
Figure 3. Expression of chemokine receptors CCR4 and CCR8 on CD25  Treg cells. (a) Cell surface expression of CCR4 and CCR8 on CD25 
Treg cells. Purified CD4 CD25  and CD4 CD25  T cells were fixed, incubated with anti-CD4, anti-CCR4, or anti-CCR8 Abs, stained with the ap-
propriate fluorochrome-conjugated secondary Abs, and analyzed by confocal microscopy. NC, not stained control. (b) Graphs illustrate the percentage of
CCR4  or CCR8 CD4  T cells counted in each subpopulation in five different fields. P values are indicated. (c) Synergistic chemotactic response to
CCL1 and CCL22 of Treg cells. CCL1 (100 ng/ml) and CCL22 (10 ng/ml) were used separately or in combination. Results are shown as chemotactic
index for Treg cells. (d) CCR8 mediates migration of Treg cells in response to CCL1. The percentage of inhibition of specific migration of Treg cells in
response to CCL1 and CCL22 (0.5  g/ml) in the presence of MC148 (2  g/ml) is shown.851 Iellem et al. Brief Definitive Report
compared the migration of CD25  and CD25  Treg cells
in response to supernatants of mature DCs and investigated
the role of CCL17 and CCL22 present in the supernatants.
Our data show that supernatant obtained from mature DCs
preferentially attracted CD25  Treg cells among blood-borne
CD4  T cells (Fig. 4). Neutralization of CCL22 significantly
reduced the migration of Treg cells, but neutralization of
both CCL17 and CCL22 was required to completely abol-
ish the migration of Treg cells (Fig. 4).
Discussion
In this report, we provide the first evidence that blood-
borne human CD4 CD25  Treg cells exhibit a distinctive
chemotactic response profile and chemokine receptor ex-
pression. Treg cells exhibit chemotactic responsiveness to
several inflammatory and lymphoid chemokines, but they
are specifically hyperresponsive to chemokines that engage
the chemokine receptors CCR4 and CCR8 (Fig. 1).
Our investigation documents a broad spectrum of re-
sponsiveness of Treg cells to inflammatory chemokines that
could potentially allow access to inflamed tissues and con-
tact responding T cells and APCs. However, the specificity
of action of chemokines such as CCL17, CCL22, and
CCL1 on Treg cells suggests a unique role for these
chemokines and their receptors in the physiology of Treg
cells. Activated T cells and professional APCs such as DCs
and monocytes/macrophages can produce CCL1, CCL17,
and CCL22 (15, 16, 18). CCL17 and CCL22 secreted by
activated DCs have been shown to attract activated T cells
expressing CCR4 (17). Recent data suggest that T cells
compete for access to antigen-bearing APCs (19, 20), a
phenomenon that may potentially be regulated by
chemokines secreted by APCs and chemokine receptors
expressed on T cells. Thus, chemokine receptors, such as
CCR4 and CCR8, that are upregulated upon TCR-medi-
ated activation and are associated to critical steps of Th cell
differentiation (21), may regulate the access of T cells to
antigen-bearing APCs and control the dynamics of their
interactions. In light of our results, we speculate that con-
stitutive expression of CCR4 and CCR8 may endow Treg
cells with a competitive advantage over other T cells for in-
teracting with APCs that secrete chemokines acting on
those receptors. Consistent with this hypothesis, we found
that mature DCs preferentially attract Treg cells among cir-
culating CD4  T cells by virtue of their secretion of
CCR4 agonistic chemokines. Another possible scenario,
not mutually exclusive, envisions that the production of
CCL1, CCL17, and CCL22 by different types of cells in
inflamed tissues may recruit Treg cells to downregulate an
ongoing inflammatory response. In line with this proposal,
the previously reported pattern of CCL1 secretion by Fc 
receptor triggered monocytes is consistent with chemo-
kines produced in an inflammatory environment in response
to opsonizing Abs and bacterial products (16). Interestingly,
Fc RI triggering has been implicated in downregulation of
inflammatory responses by modulating cytokine produc-
tion by monocytes (22). Furthermore, we have recently
shown that IL-12 inhibits CCL1 and CCL22 production
by activated T cells (18). Conceivably, production of
CCL1 and CCL22 by activated monocytes and T cells (15,
18, 23) might promote the recruitment of Treg cells to
downregulate inflammatory Th1 responses (24).
Specific expression of CCR4 and CCR8 on Treg cells
may allow their migration toward APCs and activated T
cells leading to inhibition of APC function or suppression
of responding T cells. Although Treg cells specifically ex-
press both CCR4 and CCR8, there are important distinc-
tions between these receptors. First, CCR8 appears more
selectively expressed on Treg cells than CCR4. CCR4 is
expressed on the majority of circulating CD4  memory T
cells, including skin-homing T cells and central memory
CCR7  T cells (12, 25, 26; Fig. 3 a). By contrast, CCR8
expression and responsiveness to CCL1 seems confined
to Treg cells and to another small subset of circulating
CD4  T cells (unpublished data). Second, CCR4 agonistic
chemokines are consistently more potent and efficacious
than CCR8 agonistic chemokines in promoting migration
Figure 4. Production of
CCL17 and CCL22 by mature
human DCs leading to preferen-
tial attraction of CD25  Treg
cells. Human monocyte-derived
DCs were washed and stimulated
with LPS. DCs were washed
again after 16 h and cultured
for additional 24 h before har-
vesting the supernatants. Super-
natants were tested for their che-
motactic activity on CD4  T
cells. Chemotactic index of
CD4 CD25  (black bars) and
CD4 CD25  (white bars) T
cells is indicated. Where indi-
cated, isotype-matched control
(ctrl) or anti-CCL17 and/or
anti-CCL22 mAbs (2  g/ml)
were added to the supernatants to remove the investigated chemokine as described in Materials and Methods. Migration to CCL22 is shown for com-
parison. Results are from one representative experiment of two performed.852 Specific Expression of CCR4 and CCR8 on CD4 CD25  Regulatory T Cells
of Treg cells. This difference may be due to different levels
of chemokine receptor’s expression and could imply a dis-
tinct involvement for CCR4 and CCR8 in the function of
Treg cells.
Based on our findings, regulation of CCL1, CCL17, and
CCL22 production during the course of inflammatory re-
sponses could dictate the extent, severity, and duration of
the response by modulating recruitment of Treg cells ex-
pressing CCR4 and CCR8. Interestingly, HHV8, which is
found associated with Kaposi’s sarcoma and Castelman’s
disease, encodes for three viral chemokines (vMIP-I, II,
and III), which are believed to play a role in subverting the
host’s immune response (27). vMIP-I and vMIP-II are se-
lective agonists of CCR8 (28, 29), while vMIP-III is an ag-
onist of CCR4 (30). Based on our findings, we can specu-
late that production of vMIPs by HHV8 may recruit Treg
cells in infected tissues and help virally infected cells to
evade the host’s immune response. Taken together, our
data suggest that certain “regulatory” chemokines may
control the termination of inflammatory responses by re-
cruiting a specific subset of Treg cells that can limit tissue
damage and prevent autoimmunity. Manipulating the re-
cruitment of Treg cells may be useful in a variety of patho-
logical conditions to either achieve tolerance in autoimmu-
nity and transplantation or boost immune responses against
tumors and viral infections.
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